Sign in
Taking peoplePhase 2

A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure

Key facts

Who runs it
MiNK Therapeutics
Where
Houston, San Antonio, and San Francisco, United StatesSee the 3 sitesAlso in 1 other country, 1 site
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
90 people, planned
Started
26 May 2026
Expected to end
Aug 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • agenT-797
  • Placebo
  • Standard of Care (SOC)
Record updated
26 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based on clinical suspicion
  • Acute hypoxemic respiratory failure (AHRF)
  • Evidence of moderate to severe acute respiratory distress syndrome (ARDS) based on Global ARDS criteria
  • Onset of severe pneumonia with AHRF ≤7 days prior to informed consent

Who cannot take part

  • Current participation in another interventional clinical trial, or receipt of an investigational medicinal product within 30 days prior to screening, unless reviewed and approved in writing by the medical monitor; Note: Other protocol-defined inclusion/exclusion criteria may apply
  • History of cytokine release syndrome, as documented in the medical record or reported by the participant, legally authorized representative, or close relative
  • More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent
  • Pregnancy or breastfeeding

Where in United States

Also in 1 other country, 1 site

  • Children's Memorial Hermann HospitalHouston, United StatesContact: Charles Cox, MD (principal investigator)Not yet recruiting
  • University HospitalSan Antonio, United StatesContact: Donald Jenkins, MD (principal investigator)Not yet recruiting
  • UCSF Medical Center at Parnassus HeightsSan Francisco, United StatesContact: Michael Matthay, MD (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).

The 2 groups in the trial

  • agenT-797 plus SOCTreatment being tested

    Participants will receive agenT-797 and SOC.

    Treatment: agenT-797 and Standard of Care (SOC)

  • Placebo plus SOCPlacebo, for comparison

    Participants will receive placebo and SOC.

    Treatment: Placebo and Standard of Care (SOC)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria
Record updated
26 June 2026